New research reveals promising drug targets to block coronaviruses at multiple stages of infection—even across different ...

CLN2, a form of Batten disease, is a pediatric neurodegenerative disorder with an estimated incidence of 0.5 per 100,000 live ...

The new facility represents a part of of Gilead Sciences' $32 billion vision for delivering next generation therapies.

Findings add to growing evidence indicating how environmental factors may trigger harmful protein changes in the brain that ...

Ability of HSPCs in space to make healthy new cells declined, while signs of molecular wear-and-tear became more pronounced.

In this GEN webinar, viewers will gain a deeper understanding of the technology and operational expertise required to navigate the challenges of ultra-short shelf lives, ensuring these potent ...

Paola Romagnani, MD, PhD, speaks with GEN about estrogen-driven regeneration of podocytes having a protective effect on CKD and preeclampsia.

Novartis has agreed to license and develop Arrowhead Pharmaceuticals’ preclinical stage small interfering RNA (siRNA) therapy ...

A customizable protein, Crunch, harnesses the body’s natural cleanup system to remove harmful cells, opening new potential ...

Electrical stimulation of macrophages could represent a new therapy to boost the body’s own repair processes in a range of ...

The data shows that tweaks to csp15 peptide in cold-shock proteins, expands the range of microbes that plant immune systems can recognize ...

Elena Erroba is the group CCO at 3PBIOVIAN. She specializes in the development and manufacturing of recombinant proteins and advanced therapies, including viral vectors—such as adenoviruses and ...